175 related articles for article (PubMed ID: 23747573)
1. Agonists and antagonists induce different palonosetron dissociation rates in 5-HT₃A and 5-HT₃AB receptors.
Lummis SC; Thompson AJ
Neuropharmacology; 2013 Oct; 73():241-6. PubMed ID: 23747573
[TBL] [Abstract][Full Text] [Related]
2. Exploring a potential palonosetron allosteric binding site in the 5-HT(3) receptor.
Del Cadia M; De Rienzo F; Weston DA; Thompson AJ; Menziani MC; Lummis SC
Bioorg Med Chem; 2013 Dec; 21(23):7523-8. PubMed ID: 24128813
[TBL] [Abstract][Full Text] [Related]
3. VUF10166, a novel compound with differing activities at 5-HT₃A and 5-HT₃AB receptors.
Thompson AJ; Verheij MH; de Esch IJ; Lummis SC
J Pharmacol Exp Ther; 2012 May; 341(2):350-9. PubMed ID: 22306960
[TBL] [Abstract][Full Text] [Related]
4. Prolonged inhibition of 5-HT₃ receptors by palonosetron results from surface receptor inhibition rather than inducing receptor internalization.
Hothersall JD; Moffat C; Connolly CN
Br J Pharmacol; 2013 Jul; 169(6):1252-62. PubMed ID: 23581504
[TBL] [Abstract][Full Text] [Related]
5. Palonosetron exhibits unique molecular interactions with the 5-HT3 receptor.
Rojas C; Stathis M; Thomas AG; Massuda EB; Alt J; Zhang J; Rubenstein E; Sebastiani S; Cantoreggi S; Snyder SH; Slusher B
Anesth Analg; 2008 Aug; 107(2):469-78. PubMed ID: 18633025
[TBL] [Abstract][Full Text] [Related]
6. Palonosetron-5-HT
Price KL; Lillestol RK; Ulens C; Lummis SC
ACS Chem Neurosci; 2016 Dec; 7(12):1641-1646. PubMed ID: 27656911
[TBL] [Abstract][Full Text] [Related]
7. Discriminating between 5-HT₃A and 5-HT₃AB receptors.
Thompson AJ; Lummis SC
Br J Pharmacol; 2013 Jun; 169(4):736-47. PubMed ID: 23489111
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and Pharmacological Evaluation of [
Mu L; Müller Herde A; Rüefli PM; Sladojevich F; Milicevic Sephton S; Krämer SD; Thompson AJ; Schibli R; Ametamey SM; Lochner M
ACS Chem Neurosci; 2016 Nov; 7(11):1552-1564. PubMed ID: 27571447
[TBL] [Abstract][Full Text] [Related]
9. Palonosetron triggers 5-HT(3) receptor internalization and causes prolonged inhibition of receptor function.
Rojas C; Thomas AG; Alt J; Stathis M; Zhang J; Rubenstein EB; Sebastiani S; Cantoreggi S; Slusher BS
Eur J Pharmacol; 2010 Jan; 626(2-3):193-9. PubMed ID: 19836386
[TBL] [Abstract][Full Text] [Related]
10. The interaction of RS 25259-197, a potent and selective antagonist, with 5-HT3 receptors, in vitro.
Wong EH; Clark R; Leung E; Loury D; Bonhaus DW; Jakeman L; Parnes H; Whiting RL; Eglen RM
Br J Pharmacol; 1995 Feb; 114(4):851-9. PubMed ID: 7773546
[TBL] [Abstract][Full Text] [Related]
11. The antiemetic 5-HT3 receptor antagonist Palonosetron inhibits substance P-mediated responses in vitro and in vivo.
Rojas C; Li Y; Zhang J; Stathis M; Alt J; Thomas AG; Cantoreggi S; Sebastiani S; Pietra C; Slusher BS
J Pharmacol Exp Ther; 2010 Nov; 335(2):362-8. PubMed ID: 20724484
[TBL] [Abstract][Full Text] [Related]
12. Broad-spectrum antiemetic potential of the L-type calcium channel antagonist nifedipine and evidence for its additive antiemetic interaction with the 5-HT(3) receptor antagonist palonosetron in the least shrew (Cryptotis parva).
Darmani NA; Zhong W; Chebolu S; Vaezi M; Alkam T
Eur J Pharmacol; 2014 Jan; 722():2-12. PubMed ID: 24513517
[TBL] [Abstract][Full Text] [Related]
13. The C and E subunits of the serotonin 5-HT
Yaakob NS; Nguyen DT; Exintaris B; Irving HR
Biomed Pharmacother; 2018 Jan; 97():1701-1709. PubMed ID: 29793334
[TBL] [Abstract][Full Text] [Related]
14. Theoretical evaluation of antiemetic effects of 5-HT3 receptor antagonists for prevention of vomiting induced by cisplatin.
Nakamura H; Yokoyama H; Takayanagi R; Yoshimoto K; Nakajima A; Okuyama K; Iwase O; Yamada Y
Eur J Drug Metab Pharmacokinet; 2015 Mar; 40(1):39-44. PubMed ID: 24470169
[TBL] [Abstract][Full Text] [Related]
15. 5-Chloroindole: a potent allosteric modulator of the 5-HT₃ receptor.
Newman AS; Batis N; Grafton G; Caputo F; Brady CA; Lambert JJ; Peters JA; Gordon J; Brain KL; Powell AD; Barnes NM
Br J Pharmacol; 2013 Jul; 169(6):1228-38. PubMed ID: 23594147
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of substance P-mediated responses in NG108-15 cells by netupitant and palonosetron exhibit synergistic effects.
Stathis M; Pietra C; Rojas C; Slusher BS
Eur J Pharmacol; 2012 Aug; 689(1-3):25-30. PubMed ID: 22683863
[TBL] [Abstract][Full Text] [Related]
17. The binding characteristics and orientation of a novel radioligand with distinct properties at 5-HT3A and 5-HT3AB receptors.
Thompson AJ; Verheij MH; Verbeek J; Windhorst AD; de Esch IJ; Lummis SC
Neuropharmacology; 2014 Nov; 86():378-88. PubMed ID: 25174552
[TBL] [Abstract][Full Text] [Related]
18. Discovery of a novel allosteric modulator of 5-HT3 receptors: inhibition and potentiation of Cys-loop receptor signaling through a conserved transmembrane intersubunit site.
Trattnig SM; Harpsøe K; Thygesen SB; Rahr LM; Ahring PK; Balle T; Jensen AA
J Biol Chem; 2012 Jul; 287(30):25241-54. PubMed ID: 22589534
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic action of 5-HT3 receptor antagonists targeting peritoneal macrophages in post-operative ileus.
Maehara T; Matsumoto K; Horiguchi K; Kondo M; Iino S; Horie S; Murata T; Tsubone H; Shimada S; Ozaki H; Hori M
Br J Pharmacol; 2015 Feb; 172(4):1136-47. PubMed ID: 25377620
[TBL] [Abstract][Full Text] [Related]
20. Superagonist, Full Agonist, Partial Agonist, and Antagonist Actions of Arylguanidines at 5-Hydroxytryptamine-3 (5-HT
Alix K; Khatri S; Mosier PD; Casterlow S; Yan D; Nyce HL; White MM; Schulte MK; Dukat M
ACS Chem Neurosci; 2016 Nov; 7(11):1565-1574. PubMed ID: 27533595
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
